摘要
目的:讨论Ⅱ型前列腺炎患者前列腺结石、前列腺液白细胞数及临床症状相关性。方法:我院门诊2009年1月至2011年12月就诊的327例Ⅱ型前列腺炎患者纳入研究。所有患者治疗前均行前列腺液白细胞计数、经腹前列腺彩超和慢性前列腺炎症状指数评分(CPSI),将结果进行统计学分析。结果:所有Ⅱ型前列腺炎患者的前列腺结石直径和前列腺液中白细胞计数两者有相关性,差异具有统计学意义(P<0.05),前列腺结石直径和NIH-CPSI评分、前列腺液白细胞计数和NIH-CPSI评分均无相关性(P>0.05)。根据前列腺结石直径将患者进行分组,不同组别的患者的前列腺液白细胞计数不同,其差异有统计学意义(P<0.05),NIH-CPSI评分组间差异无统计学意义(P>0.05)。结论:Ⅱ型前列腺炎患者就诊时前列腺结石、前列腺液白细胞计数和前列腺炎患者临床症状无明细相关性,因此Ⅱ型前列腺炎患者前列腺结石情况和前列腺液白细胞计数一样不能作为独立因素评估前列腺炎的临床症状的严重性并用于指导治疗。
Objective: To discuss the correlation among Prostatic calculi, the amount of leukocyte in expressed prostatic secretion (EPS) and National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) in men with chronic bacterial prostatitis. Method: 327 patients with chronic bacterial prostatitis were enrolled between January 2009 and December 2011. All patients accepted the amount of leukocyte in EPS, ultrasonic diagnosis in prostate, and National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) was used to measure symptoms. Data was collected and analysis. Results: There was correlation between the diameter of prostatic calculi and the amount of leukocyte in EPS (P〈0.05). There was no correlation neither between the amount of leukocyte in EPS and NIH-CPSI scores (P〉0.05), nor between prostatic calculi and NIH-CPSI scores (P〉0.05). With different groups divided according diameter of prostatic calculi, the amount of leukocyte in EPS was significant difference(P〈0.05), but there was no significant difference in NIH-CPSI scores(P〉0.05). Conclusion: Because there was no correlation neither between the amount of leukocyte in EPS and NIH-CPSI scores, nor between the diameter of prostatic calculi and NIH-CPSI scores, neither the amount of leukocyte in EPS nor the diameter of prostatic calculi could be used as a tool to assess for clinical symptom or Guiding for treatment in men with chronic bacterial prostatitis.
出处
《现代生物医学进展》
CAS
2013年第20期3920-3922,共3页
Progress in Modern Biomedicine